MedPath

Antioxidant and Immune Effects of Vitamin K2

Not Applicable
Completed
Conditions
Oxidative Stress
Inflammation
Interventions
Dietary Supplement: Vitamin K2
Dietary Supplement: Placebo
Registration Number
NCT05675163
Lead Sponsor
NIZO Food Research
Brief Summary

The aim of the study is to obtain insight into a dose-dependent effect of vitamin K2 on oxidative stress and specific markers of the immune system.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Self-reported postmenopausal (at least one year after the final menstruation)
  • BMI ≥25 and ≤32 kg/m2;
  • Plasma dp-ucMGP concentration in highest 50-66% of the screened population
  • Non-smoking, defined as not smoking currently and not having smoked (at all) in the year before study start;
  • Healthy as assessed by the health questionnaire and according to the judgment of the study physician;
  • Voluntary participation;
  • Having given written informed consent;
  • Willing to comply with study procedures;
Exclusion Criteria
  • Plasma dp-ucMGP concentration >1000 pmol/L at screening
  • Treatment with oral antibiotics within 2 months of the start of the study
  • Any vaccination in the month before study start or any scheduled vaccination during the study period
  • Use of antioxidant or vitamin K and D supplements;
  • Use of antioxidant or vitamin K and D supplements in the month before the start of the study;
  • Use of aspirin or medication with established antioxidant or anti-inflammatory properties;
  • Use of medication that interferes with vitamin K or blood coagulation;
  • Use of statins to reduce level of low-density lipoprotein cholesterol in the blood;
  • Hyperlipidaemia, diabetes, hypertension, intestinal disease, diseases with an inflammation component;
  • Hormone replacement therapy in women;
  • Follow a vegetarian or vegan diet;
  • Participation in any clinical trial including blood sampling and/or administration of substances up to 30 days before day 1 of this study;
  • Alcohol consumption for men > 28 units/week and >4/day; for women: >21 units/week and >3/day;
  • Reported unexpected weight loss or weight gain of > 3 kg in the month prior to pre-study screening, or intention to lose weight during the study period;
  • Reported slimming or medically prescribed diet;
  • Recent blood donation (<1 month prior to Day 01 of the study);
  • Not willing to give up blood donation during the study;

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Vitamin K2 low dosePlacebo333 μg/d Vitamin K2 (MK-7)
PlaceboPlacebomatched dose of sunflower oil
Vitamin K2 high doseVitamin K2666 μg/d Vitamin K2 (MK-7)
Vitamin K2 low doseVitamin K2333 μg/d Vitamin K2 (MK-7)
Primary Outcome Measures
NameTimeMethod
plasma ox-LDL3 weeks

Dose dependent change in ox-LDL levels

Secondary Outcome Measures
NameTimeMethod
plasma CRP3 weeks

Dose dependent change in plasma CRP levels

IL-63 weeks

Dose dependent change in plasma IL-6 levels

plasma MDA3 weeks

Dose dependent change in plasma MDA levels

Phagocytosis capacity3 weeks

% positive and MFI of monocytes and granulocytes

PBMC gene expression3 weeks

Differential Gene Expression analysis (DGE) - Fold change and relative abundance

Trial Locations

Locations (1)

NIZO food research

🇳🇱

Ede, Netherlands

© Copyright 2025. All Rights Reserved by MedPath